Navigation Links
UK's National Health System Rejects Drug Therapy for Diabetic Macular Edema

MOUNTAIN VIEW, Calif., Dec. 13, 2011 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued a final guidance which determined that Novartis AG's drug Lucentis is not as cost effective as conventional laser photocoagulation treatment and rejected the leading drug therapy as a treatment for diabetic macular edema (DME), a swelling of retinal tissue and the most common cause of vision loss in diabetics. The rejection means that the UK National Health Service (NHS) currently will not pay for drug therapy with Lucentis for DME treatment in diabetic patients, thereby creating another important opportunity for advanced laser treatments such as IRIDEX' MicroPulse laser therapy, which has shown to be as effective as conventional laser photocoagulation with no associated retina tissue damage.

NICE, an independent appraisal committee which the UK NHS relies upon, determined that the benefits derived by Lucentis do not justify its cost; and that laser photocoagulation represented better value for NHS resources. "While Novartis is certain to appeal the ruling, this is an important indication that DME patients should consider other options besides drug therapy," noted Dominik Beck, PhD., IRIDEX President and CEO.

"This is a very clear and important statement by one of the most important medical care payers in the world: drugs are not a panacea for retinal diseases," Dr. Beck said. "Drugs like Lucentis certainly have a role in ophthalmology and can be an excellent and safe treatment for acute DME, but in addition to high costs, they come with side effects and questions about their long term benefits. That's among the reasons why we now offer MicroPulse technology on all of our new laser systems and why MicroPulse technology should be considered a first line treatment for most forms of DME. Numerous recent studies show that MicroPulse technology can provide significant durable benefits for diabetes patients without damaging the retina; thus providing powerful economic advantages for both the payors and patients."

DME is a rapidly expanding retinal disorder. Up to 10% of all diabetics will develop DME during their lifetime. Detecting and treating diabetic eye disease with laser therapy can reduce the development of severe vision loss by an estimated 50% to 60%.

About MicroPulse Technology

MicroPulse is a tissue-sparing laser therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.

About IRIDEX Corporation

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to opportunities for advanced laser treatments, the Company's MicroPulse technology, the economic and therapeutic benefits of this technology and the Company's growth strategy.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and our Quarterly Reports on Form 10-Q for the quarters ended April 2, 2011, July 2, 2011 and October 1, 2011, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.                                                                                                                                                                    

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. International Isotopes Inc. Announces Conference Call to Give an Update on the Companys General Business Status
2. NHS National Innovation Centre Estimates Sequana Medicals ALFApump® System Could Save the NHS £50 Million in ascites Care Annually
3. IBM Contributes Data to the National Institutes of Health to Speed Drug Discovery and Cancer Research Innovation
4. New MediCare International Excess Options Give up to 50% Premium Discount
5. Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
6. Chindex International, Inc. to Present at the 22nd Annual Oppenheimer Healthcare Conference
7. National Foundation for Infectious Diseases Supports 2011 National Influenza Vaccination Week
8. National Influenza Vaccination Week is December 4 - 10, 2011
9. Bupa International Releases Health Guides to Hong Kong and Singapore
10. Leading Indian CRO Max Neeman International Expands in Response to Positive Biosimilars Market in India
11. National Coalition Continues Fight to Stop the Express Scripts/Medco Merger in Nations Capitol
Post Your Comments:
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at ... Michigan, have come together on Thanksgiving Day to share the things that they ... on the Serenity Point YouTube channel, patients displayed what they wrote on index ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and in ... by healthcare staffing agency Aureus Medical Group . These fields, as ... among those searching for healthcare jobs through the company’s website, , ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... been recognized once again for its stellar workplace culture with the company’s Cincinnati ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business ...
Breaking Medicine News(10 mins):